Loading...
XNYSPEN
Market cap9.68bUSD
Jan 07, Last price  
252.23USD
1D
6.30%
1Q
27.68%
Jan 2017
295.34%
IPO
530.58%
Name

Penumbra Inc

Chart & Performance

D1W1MN
XNYS:PEN chart
P/E
106.43
P/S
9.15
EPS
2.37
Div Yield, %
0.00%
Shrs. gr., 5y
1.68%
Rev. gr., 5y
18.93%
Revenues
1.06b
+24.95%
73,141,00088,848,000125,510,000186,095,000263,317,000333,764,000444,938,000547,405,000560,412,000747,590,000847,133,0001,058,522,000
Net income
91m
P
1,958,0004,099,0002,245,0002,365,00014,814,0004,657,0006,601,00048,458,000-19,257,0002,623,000-2,002,00090,954,000
CFO
97m
P
-3,396,000-6,389,000-22,279,000-12,807,00012,691,00028,808,00026,652,000-33,242,0009,502,000-55,661,00097,333,000
Earnings
Feb 20, 2025

Profile

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
IPO date
Sep 18, 2015
Employees
3,900
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,058,522
24.95%
847,133
13.32%
Cost of revenue
966,756
841,051
Unusual Expense (Income)
NOPBT
91,766
6,082
NOPBT Margin
8.67%
0.72%
Operating Taxes
(11,304)
5,894
Tax Rate
96.91%
NOPAT
103,070
188
Net income
90,954
-4,643.16%
(2,002)
-176.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,822
5,724
BB yield
-0.13%
-0.07%
Debt
Debt current
26,868
11,953
Long-term debt
455,252
459,593
Deferred revenue
Other long-term liabilities
5,308
3,276
Net debt
212,872
283,516
Cash flow
Cash from operating activities
97,333
(55,661)
CAPEX
(15,213)
(19,298)
Cash from investing activities
(16,076)
54,790
Cash from financing activities
16,203
11,622
FCF
26,356
(185,007)
Balance
Cash
289,187
188,030
Long term investments
(19,939)
Excess cash
216,322
145,673
Stockholders' equity
131,746
35,818
Invested Capital
1,300,283
1,202,089
ROIC
8.24%
0.02%
ROCE
6.41%
0.49%
EV
Common stock shares outstanding
39,217
37,842
Price
251.54
13.07%
222.46
-22.57%
Market cap
9,864,535
17.18%
8,418,303
-22.65%
EV
10,077,407
8,701,819
EBITDA
119,023
30,403
EV/EBITDA
84.67
286.22
Interest
1,739
137
Interest/NOPBT
1.90%
2.25%